Melanogenesis and melanoma

Pigment Cell Research

Volumn 16, Issue 5, 2003, Pages 548-552

  Riley, Patrick A ^a  

^a Totteridge Institute for Advanced Studies   (United Kingdom)

Author keywords

Chemotherapy; Genoprotection; Immunotherapy; Photoprotection; Tyrosinase

Indexed keywords

MELANIN; MONOPHENOL MONOOXYGENASE; QUINONE DERIVATIVE;

CYTOTOXICITY; DENDRITIC CELL; HUMAN; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOSOME; NONHUMAN; REVIEW; SKIN CANCER; SKIN PROTECTION; SUN EXPOSURE;

ANIMALS; HUMANS; MELANINS; MELANOCYTES; MELANOMA; MELANOSOMES; MOLECULAR STRUCTURE; NEOPLASMS, RADIATION-INDUCED;

EQUUS CABALLUS; VERTEBRATA;

EID: 0041335218     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0749.2003.00069.x     Document Type: Review

References (50)

1. Prota G. Melanin and Melanogenesis. San Diego: Academic Press; 1992
2. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988;124:869-871
3. Clancy CM, Simon JD. Ultrastructural organization of eumelanin from Sepia officianalis measured by atomic force microscopy. Biochemistry 2001;40:13353-13360
4. Boissy RE. Extracutaneous melanocytes. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne J-P. The Pigmentary System. New York: OUP; 1998. pp. 59-73
5. Riley PA. A theoretical note on the topological features of melanin transfer. Brit J Dermatol 1978;99:107-110
6. Riley PA. Melanogenesis: a realistic target for antimelanoma therapy? Eur J Cancer 1991;27:1172-1177
7. Riley PA. Epidermal melanin: sun screen or waste disposal? Biologist 1997;44:408-411
8. Land EJ, Ramsden CA, Riley PA. Tyrosinase autoactivation and the chemistry of ortho-quinone amines. Acc Chem Res 2003;36:300-308
9. Riley PA. Dendritic cell populations of the epidermis. In: Jarrett A. The Physiology and Pathophysiology of the Skin. London: Academic Press; 1975. pp. 1101-1130
10. English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer 1998;76:628-634
11. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000;25:459-463
12. Cress RD, Holly EA, Ahn DK. Cutaneous melanoma in women. V. Characteristics of those who tan and those who burn when exposed to summer sun. Epidemiology 1995;6:538-543
13. Zanetti R, Prota G, Napolitano A, Martinez C, Sancho-Garnier H, Osterlind A, Sacerdote C, Rosso S. Development of an integrated method of skin phenotype measurement using the melanins. Melanoma Res 2001;11:551-557
14. Chedekel MR, Smith SK, Post PW, Pokora A, Vessell DL. Photodestruction of pheomelanin: role of oxygen. Proc Natl Acad Sci USA 1978;75:5395-5399
15. Pavel S, Smit NMP, van der Meulen H, Kolb RM, de Groot AJL, van der Velden PA, Gruis NA, Bergman W. Homozygous germline mutation of CDKN2A/p16 and glucose-6-phosphate dehydrogenase deficiency in a multiple melanoma case. Melanoma Res 2003;13:171-178
16. Hochstein P, Cohen G. The cytotoxicity of melanin precursors. Ann N Y Acad Sci 1963;100:876-881
17. Smit NPM, Pavel S, Riley PA. Mechanisms of control of the cytotoxicity of orthoquinone intermediates of melanogenesis. In: Creveling CR. Role of Catechol Quinone Species in Cellular Toxicity. Johnson City: FP Graham Publishing; 1999. pp. 191-245
18. Hara H, Lee MH, Chen H, Luo D, Jimbow K. Role of gene expression and protein synthesis of tyrosinase, TRP-1, lamp-1, and CD63 in UVB-induced melanogenesis in human melanomas. J Invest Dermatol 1994;102:495-500
19. Borovansky J, Mirejovsky P, Riley PA. Possible relationship between abnormal melanosome structure and cytotoxic phenomena in malignant melanoma. Neoplasma 1991;38:393-400
20. Borovansky J. Properties of melanosomes and their exploitation in the diagnosis and treatment of melanoma. Melanoma Res 1993;3:181-186
21. Prichard RS, Dijkstra B, McDermott EW, Hill AD, O'Higgins DNJ. The role of molecular staging in malignant melanoma. Eur J Surg Oncol 2003;29:306-314
22. Pavel S. Eumelanin-related compounds, their metabolism and clinical relevance. Amsterdam: Rodopi Press; 1988
23. Wick MM, Byers L, Ratliff J. Selective toxicity of 6-hydroxydopa for melanoma cells. J Invest Dermatol 1979;72:67-69
24. Lin AJ, Kelley JA, Breitman TR, Driscoll JS. Agents with potential specificity against melanotic melanoma. J Med Chem 1982;25:501-505
25. Morrison ME, Yagi MJ, Cohen G. In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells. Proc Natl Acad Sci USA 1985;82:2960-2964
26. Riley PA. Radicals and melanomas. Philos Trans R Soc Lond B Biol Sci 1985;311:679-689
27. Kern DH, Shoemaker RH, Hildebrand-Zanki SU, Driscoll JS. Structure-activity relationships defining the cytotoxicity of catechol analogues against human malignant melanoma. Cancer Res 1988;48:5178-5182
28. Kulkarni GA, Nathanson L. Specificity of growth inhibition of melanoma by 4-hydroxyanisole. Pigment Cell Res 1989;2:40-43
29. Alena F, Jimbow K, Ito S. Melanocytotoxicity and antimelanoma effects of phenolic amine compounds in mice in vivo. Cancer Res 1990;50:3743-3747
30. Miura T, Jimbow K, Ito S. The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its n-acetyl derivative. Int J Cancer 1990;46:931-934
31. Parsons PG, Favier D, McEwan M, Takahashi H, Jimbow K, Ito S. Action of cysteaminylphenols on human melanoma cells in vivo and in vitro: 4-S-cysteaminylphenol binds protein disulphide isomerase. Melanoma Res 1991;1:97-104
32. Mascagna D, Ghanem G, Morandini R, d'Ischia M, Misuraca G, Lejeune F, Prota G. Synthesis and cytotoxic properties of new N-substituted 4-aminophenol derivatives with a potential as antimelanoma agents. Melanoma Res 1992;2:25-32
33. Hasegawa K, Ito S, Inoue S, Wakamatsu K, Ozeki H, Ishiguro I. Dihydro-1,4-benzothiazine-6,7-dione, the ultimate toxic metabolite of 4-S-cysteaminylphenol and 4-S-cysteaminylcatechol. Biochem Pharmacol 1997;53:1435-1444
34. Inoue S, Hasegawa K, Wakamatsu K, Ito S. Comparison of antimelanoma effects of 4-S-cysteaminylphenol and its homologues. Melanoma Res 1998;8:105-112
35. Gili A, Thomas PD, Ota M, Jimbow K. Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity. Melanoma Res 2000;10:9-15
36. Lant NJ, McKeown P, Timoney MC, Kelland LR, Rogers PM, Robins DJ. Synthesis and anti-melanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol substituted with two methyl groups alpha to the nitrogen. Anticancer Drug Des 2001;16:49-55
37. Naish-Byfield S, Cooksey CJ, Latter AM, Johnson CI, Riley PA. In vitro assessment of the structure-activity relationship of tyrosinase-dependent cytotoxicity of a series of substituted phenols. Melanoma Res 1991;1:273-287
38. Cooksey CJ, Jimbow K, Land EJ, Riley PA. Reactivity of orthoquinones involved in tyrosinase-dependent cytotoxicity: difference between alkylthio- and alkoxy-substituents. Melanoma Res 1992;2:283-293
39. Smit NPM, Peters K, Menko W, Westerhof W, Pavel S, Riley PA. Cytotoxicity of a series of substituted phenols towards cultured melanoma cells. Melanoma Res 1992;2:295-304
40. Cooksey CJ, Land EJ, Ramsden CA, Riley PA. Tyrosinase-mediated cytotoxicity of 4-substituted phenols: quantitative structure-thiol reactivity relationships of the derived ortho-quinones. Cancer Drug Design 1995;10:119-129
41. Riley PA. New approaches to the utilization of the melanogenic pathway in antimetanoma therapy. In: Hori Y, Hearing VJ, Nakayama J. Melanogenesis and Malignant Melanoma. Amsterdam: Elsevier; 1996. pp. 271-275
42. Cooksey CJ, Land EJ, Rushton FAP, Ramsden CA, Riley PA. Tyrosinase-mediated cytotoxicity of 4-substituted phenols: use of QSAR to forecast reactivities of thiols towards the derived orthoquinones. Quant Struct - Act Relat 1996;15:498-503
43. Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM, Ramsden CA. Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated orthoquinones in a model screening system. Eur J Canc 1997;33:135-143
44. Morgan BDG, O'Neill T, Dewey DL, Galpine AR, Riley PA. Treatment of malignant melanoma by intravascular 4-hydroxyanisole. Clin Oncol 1981;7:227-234
45. Mars U, Larsson BS. New thioureas and related substances intended for melanoma targeting. Pigment Cell Res 1995;8:194-201
46. Palumbo A, d'Ischia M, Misuraca G, Iannone A, Prota G. Selective uptake of 2-thiouracil into melanin-producing systems depends on chemical binding to enzymically generated dopaquinone. Biochim Biophys Acta 1990;1036:221-227
47. Larsson BS, Larsson B, Roberto A. Boron neutron capture therapy for malignant melanoma: an experimental approach. Pigment Cell Res 1989;2:356-360
48. 10 B molecule-melanoma cell interactions from in vitro to first clinical trial. Pigment Cell Res 1989;2:226-234
49. Jordan AM, Khan TH, Osborn HMI, Photiou A, Riley PA. Melanocyte-directed enzyme pro-drug therapy (MDEPT): development of a targeted treatment for malignant melanoma. Bioorg Med Chem 1999;7:1775-1780
50. Jordan AM, Khan TH, Malkin H, Osborn HMI, Photiou A, Riley PA. Melanocyte-directed enzyme pro-drug therapy (MDEPT): development of second-generation prodrugs for targeted treatment of malignant melanoma. Bioorg Med Chem 2001;9:1549-1558